Effects of ticlopidine on platelet function and blood coagulation.
A double blind study was performed on 20 atherosclerotic patients. A placebo was administered to one group of 10 patients (group A) and ticlopidine (500 mg/day) was administered to another group of 10 patients (group B) for one month. ADP and collagen-induced platelet aggregation (PA), platelet malondialdehyde (MDA) produced by thrombin stimulation and plasma beta-thromboglobulin (beta TG) levels, prothrombin time, activated partial thromboplastin time (APTT) fibrinogen, antithrombin (AT) III fibrin(ogen) degradation products, alpha 2-antiplasmin and plasminogen were evaluated in both groups before and after treatment. No changes in PA, MDA and beta TG were seen in group A. Group B showed a significant decrease of PA, beta TG and a significant increase of MDA. No changes on blood coagulation data were seen in either group. This study suggests that ticlopidine is able to inhibit platelet function in vivo.
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation; D010979:Platelet Function Tests; D011517:Prothrombin Time; D013876:Thiophenes / Q000494:pharmacology*; D013988:Ticlopidine; D001620:beta-Thromboglobulin / Q000032:analysis
D005338:Fibrin Fibrinogen Degradation Products; D013876:Thiophenes; D001620:beta-Thromboglobulin; D008315:Malondialdehyde; D005340:Fibrinogen; D013988:Ticlopidine